Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

A triple-hormone weight-loss drug could be a game-changer for knee arthritis sufferers. Two phase 3 trials found that retatrutide helped patients with knee osteoarthritis lose up to 25% of their body weight — and about two-thirds of those on the drug reported at least a 50% reduction in knee pain, compared to just 38% on placebo.
A powerful experimental weight-loss drug is showing remarkable promise for the millions of Americans living with painful knee osteoarthritis (OA). Two phase 3 clinical trials — TRIUMPH-1-OA and TRIUMPH-4 — led by Northwestern University and published in the New England Journal of Medicine, found that retatrutide, a once-weekly injectable developed by Eli Lilly, produced dramatic improvements in both body weight and knee pain among patients with obesity and OA.
Unlike existing GLP-1 drugs such as semaglutide or tirzepatide, retatrutide is a triple-receptor agonist, activating pathways for GLP-1, GIP, and glucagon simultaneously. This triple action appears to drive significantly greater weight loss than current options — and with that weight loss comes meaningful joint relief. Beyond pain, participants also saw improvements in blood pressure, blood lipids, and systemic inflammation markers.
By the Numbers:
Why it matters: Knee OA is notoriously difficult to treat, with most options offering only temporary or modest relief. Retatrutide could offer a meaningful new path for patients who can't achieve sufficient weight loss through diet and exercise alone — though FDA approval is still pending, and key questions about whether the drug can slow joint damage progression remain unanswered.